MET (c-Met) protein overexpression is an emerging protein biomarker in non-small cell lung cancer
8.5
来源：
Nature
关键字：
mRNA
发布时间：
2025-11-21 03:54
摘要：
MET protein overexpression (OE) is emerging as a clinically relevant biomarker in non-small cell lung cancer (NSCLC), with its prevalence ranging from 15% to 75%. This biomarker is associated with poor clinical outcomes and is actionable for targeted therapies, particularly antibody-drug conjugates. The article reviews the current evidence on MET OE, its prognostic value, and the methodologies for assessment, emphasizing the need for standardized testing protocols. As several MET-targeted therapies are in development, this area presents significant investment opportunities in oncology.
原文：
查看原文
价值分投票
评分标准
新闻价值分采用0-10分制，综合考虑新闻的真实性、重要性、时效性、影响力等多个维度。
评分越高，表示该新闻的价值越大，越值得关注。
价值维度分析
domain_focus
1.0
business_impact
1.0
scientific_rigor
1.5
timeliness_innovation
1.5
investment_perspective
2.5
market_value_relevance
1.0
team_institution_background
0.5
technical_barrier_competition
0.5
关键证据
MET protein overexpression is linked to poor clinical outcomes in NSCLC.
Several MET-targeted antibody-drug conjugates are currently in development.
High MET protein overexpression is associated with a significant proportion of patients who could benefit from targeted therapies.
真实性检查
否
AI评分总结
MET protein overexpression (OE) is emerging as a clinically relevant biomarker in non-small cell lung cancer (NSCLC), with its prevalence ranging from 15% to 75%. This biomarker is associated with poor clinical outcomes and is actionable for targeted therapies, particularly antibody-drug conjugates. The article reviews the current evidence on MET OE, its prognostic value, and the methodologies for assessment, emphasizing the need for standardized testing protocols. As several MET-targeted therapies are in development, this area presents significant investment opportunities in oncology.